https://sputnikglobe.com/20210212/russias-gamaleya-institute-completing-phase-2-trials-of-sputnik-light-single-shot-vaccine-1082054885.html
Russia's Gamaleya Institute Completing Phase 2 Trials of Sputnik Light Single-Shot Vaccine
Russia's Gamaleya Institute Completing Phase 2 Trials of Sputnik Light Single-Shot Vaccine
Sputnik International
MOSCOW (Sputnik) - Russia's Gamaleya research institute is completing the second phase of clinical trials of the Sputnik Light vaccine against the coronavirus... 12.02.2021, Sputnik International
2021-02-12T11:27+0000
2021-02-12T11:27+0000
2021-02-12T11:27+0000
https://cdn1.img.sputnikglobe.com/img/07e5/02/03/1081971934_0:157:3081:1890_1920x0_80_0_0_bfc6620ab46c2d19856061daf9ecb2ed.jpg
russia
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
newsfeed, russia, gamaleya research institute of epidemiology and microbiology
newsfeed, russia, gamaleya research institute of epidemiology and microbiology
Russia's Gamaleya Institute Completing Phase 2 Trials of Sputnik Light Single-Shot Vaccine
MOSCOW (Sputnik) - Russia's Gamaleya research institute is completing the second phase of clinical trials of the Sputnik Light vaccine against the coronavirus, institute chief Alexander Gintsburg said on Friday.
Sputnik Light is a single-shot spin-off of the Sputnik V vaccine against COVID-19.
"A month passed since it was first mentioned, and Gamaleya institute managed to conduct the first phase and is currently completing the second phase of the clinical trials," Gintsburg said, as aired by Russia-24 broadcaster.
Russia's Gamaleya research institute has also developed a technology to quickly develop vaccines against different strains of COVID-19, the director of the institute said.
"Our institute ... has developed a technology that enables very quick and efficient creation of vaccines that include antigens not to just one strain of the coronavirus ... but to two, three, four or five variants," Alexander Gintsburg said, as aired by Russia-24 broadcaster.
